Delving into the Latest Updates on Defyrus, Inc. with Synapse

概览

疾病领域	数量

感染	2
神经系统疾病	1

排名前五的药物类型	数量

单克隆抗体	1
生物药	1

排名前五的靶点	数量

Envelope (E) protein(包膜（E）蛋白)	1

关联

4

项与 Defyrus, Inc. 相关的药物

mDEF-201

靶点-

作用机制-

在研机构

Defyrus, Inc. [+1]

原研机构

Defyrus, Inc.

在研适应症

基孔肯雅热 [+6]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

ZMAb (Defyrus, Inc.)

靶点

Envelope (E) protein

作用机制

包膜（E）蛋白抑制剂

在研机构

Defyrus, Inc.

原研机构

Defyrus, Inc.

在研适应症

埃博拉病毒性疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Aderon

靶点

IFNAR

作用机制

IFNAR激动剂 [+1]

在研机构-

原研机构

Defyrus, Inc.

在研适应症-

非在研适应症

病毒感染

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Defyrus, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Defyrus, Inc. 相关的专利（医药）

登录后查看更多信息

5

项与 Defyrus, Inc. 相关的文献（医药）

2016-10-01·Antiviral Research2区 · 医学

Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge

2区 · 医学

Article

作者: Turner, Jeffrey D ; Chu, Justin Jang Hann ; Sun, Jialei ; Ennis, Jane

Enterovirus 71 (EV71) causes hand-foot-and-mouth diseases as well as neurological complications in young children. Interferon (IFN) can inhibit the replication of many viruses with low cytotoxic effects. Previously, an adenovirus vectored mouse interferon-α (DEF201), subtype 5, was generated by Wu et al, 2007. In this study, the antiviral effects of DEF201 against EV71 were evaluated in a murine model. 6-day-old BALB/c mice were administered a single dose of DEF201 before or after infection with lethal dose of EV71. The survival rate, clinical symptoms, tissue viral loads and histology pathogenesis were evaluated. IFN gene expression following a single dose of DEF201 maintained high concentrations of 100-9000 pg/mL for more than 7 days in mice serum. Pre-infection administration of a single dose of 10⁶ PFU of DEF201 offered full protection of the mice against EV71 infection compared with the empty Ad5 vector control. In addition, virus load in DEF201-treated mice muscle tissue was significantly decreased as compared with empty vector control. Histopathology analysis revealed that DEF201 significantly prevented the development of severe tissue damage with reduction of viral antigen in the murine muscle tissue. Post-infection treatment at 6 h offered full protection and partial protection at 12 h, indicating that DEF201 could be used as an anti-EV71 therapeutic agent in early stage of EV71 infection. In addition, our study showed that DEF201 enhanced the neutralization ability of serum in EV71-vaccinated mice, implying that DEF201 could promote the production of specific anti-EV71 antibodies. In conclusion, single dose of DEF201 is highly efficacious as a prophylactic agent against EV71 infection in vivo.

2014-08-01·Antiviral Research2区 · 医学

Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201)

2区 · 医学

Article

作者: Rood, Kerry A ; Turner, Jeffrey D ; Gowen, Brian B ; Julander, Justin G ; Dagley, Ashley ; Van Wettere, Arnaud J ; Ennis, Jane

Recent outbreaks of Chikungunya virus (CHIKV) infection have resulted in millions of cases of disease with significant morbidity. No approved antiviral treatments exist for the prevention or treatment of this viral disease. Infection with CHIKV results in a high rate of symptomatic disease that primarily includes a debilitating arthralgia. To model this cardinal disease manifestation, adult DBA/1J mice were challenged with CHIKV by footpad injection. Viremia and hind limb virus titers increased ∼100-fold while spleen virus increased >1000-fold within 1day post-virus infection (dpi). Footpad swelling was measured over a 10-day period, with peak swelling observed between 6 and 7dpi. Histology of the hind leg at the site of virus challenge showed evidence of myositis and synovitis starting on 5dpi. Cytokine profiling of the hind limb at the site of inoculation revealed a biphasic inflammatory response represented by an increase in IL-6, MCP-1, IFN-γ, MIP-1α, RANTES, and IL-17. To investigate the prophylactic capacity of IFN, mice were treated with mDEF201, an adenovirus-vectored IFN-α. Intranasal administration of a single 10(7)pfu/ml dose of mDEF201 administered 21days to 24h prior to infection, significantly reduced footpad swelling, virus titers in the hind leg and spleen, and several inflammatory cytokines. Efficacy was not observed when treatment was initiated 24h after virus challenge. This arthralgia model of CHIKV recapitulates relevant disease features commonly observed in human disease making it applicable to preclinical testing of therapies that target both viral replication and the associated joint disease.

2013-07-01·Journal of Virology2区 · 医学

Monoclonal Antibodies Combined with Adenovirus-Vectored Interferon Significantly Extend the Treatment Window in Ebola Virus-Infected Guinea Pigs

2区 · 医学

Article

作者: Wong, Gary ; Kobinger, Gary P. ; Fernando, Lisa ; Turner, Jeffrey D. ; Ennis, Jane ; Alimonti, Judie B. ; Qiu, Xiangguo ; Yao, Xiaojian

ABSTRACTMonoclonal antibodies (MAbs) are currently a promising treatment strategy against Ebola virus infection. This study combined MAbs with an adenovirus-vectored interferon (DEF201) to evaluate the efficacy in guinea pigs and extend the treatment window obtained with MAbs alone. Initiating the combination therapy at 3 days postinfection (d.p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i.

100 项与 Defyrus, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Defyrus, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

ZMAb (Defyrus, Inc.) ( Envelope (E) protein )	埃博拉病毒性疾病更多	临床前
mDEF-201	基孔肯雅热更多	临床前
MB-2003+ZMAb ( Envelope (E) protein )	马尔堡病毒病更多	无进展
Aderon ( IFNAR )	病毒感染更多	无进展